ZGZai-Pei Guo

Zai-Pei Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zai-Pei Guo has a total of 129 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • GWAS of Chronic Spontaneous Urticaria Reveals Genetic Overlap with Autoimmune Diseases, Not Atopic Diseases

    by Liming Zhang, Li Qiu, Jian Wu, Yumeng Qi, Xinghua Gao, Chundi He, Ruiqun Qi, Hexiao Wang, Xu Yao, Hong Zhu, et al.


  • Open Access

    IgE and IgG Anti-Thyroid Autoantibodies in Chinese Patients With Chronic Spontaneous Urticaria and a Literature Review

    by Liming Zhang, Li Qiu, Jian Wu, Yumeng Qi, Hexiao Wang, Ruiqun Qi, Xu Yao, Hong Zhu, Yuzhen Li, Siyu Hao, et al.

    Zhang L, et al. Allergy Asthma Immunol Res. 2022 Jan;14(1):131-142. https://doi.org/10.4168/aair.2022.14.1.131


  • Open Access

    HMGB1 Inhibitor Effectively Alleviates Psoriasis-Like Lesions and Inflammatory Cytokines in K14-VEGF Transgenic Mice

    by Li-Xin Fu, Bin Yin, Na Cao, Sha Qin, Xiao-Yu Lei, Tao Chen, Zai-Pei Guo

    Objective: Anti-high-mobility group box 1 (HMGB1) is involved in the pathogenesis of many inflammatory and autoimmune diseases, including psoriasis. The present study aimed to investigate the therapeutic effects of HMGB1 monoclonal antibody (mAb) in keratin 14 (K14)-vascular endothelial growth factor (VEGF) transgenic homozygous mice. Methods: Twelve VEGF transgenic mice were randomly divided into two groups of six mice each: the anti-HMGB1 mAb group and the immune complex (IC) mAb group. The mice underwent intraperitoneal injection of anti-HMGB1 mAb or IC mAb once every 2 days for a total of three treatments. Compare the lesions on the ears of the mice and evaluate the severity of the lesions using the baseline and clinical scores on the last day of treatment. The changes in psoriasis-like lesions, cellular infiltration of T cells, dendritic cells, and neutrophils were detected by hematoxylin–eosin staining and immunohistochemistry. The mRNA expression of the inflammatory cytokines, including interleukin (IL)-6, tumor necrosis factor-α, interferon-γ, and IL-17 in the lesions were assessed by real-time quantitative polymerase chain reaction. The number of γ δ T cells in the lesions of two groups were detected by flow cytometry. The t test was used to compare their differences. Results: The anti-HMGB1 mAb effectively ameliorated the clinical skin lesions. The clinical scores in the anti-HMGB1 mAb group were lower than those in the IC mAb group (6.00 ± 0.52 vs. 10.83 ± 0.48, P < 0.001). Histopathologic changes and improvements in the K14-VEGF transgenic homozygous mice were evident after three treatments. The scores of mice in the anti-HMGB1 mAb group were significantly lower than those in the IC mAb group (3.25 ± 0.71 vs. 6.95 ± 0.83, P = 0.0033). The average epidermal thickness in the anti-HMGB1 mAb group was reduced by about 45% when compared with that in the IC mAb group (32.15 ± 7.08 vs. 64.69 ± 7.93, P = 0.0054). Moreover, anti-HMGB1 mAb also decreased the number of infiltrating CD3+ T cells, myeloperoxidase-positive neutrophils, and CD11c+ dendritic cells. The ratio of ear skin γ δ T cells was reduced in anti-HMGB1 mAb treated group. The mRNA expression of IL-6, tumor necrosis factor-α, interferon-γ, and IL-17 in the anti-HMGB1 mAb group were significantly reduced when compared with IC mAb group (0.36 ± 0.070 vs.1.98 ± 0.62, P = 0.0148; 6.43 ± 1.37 vs. 13.80 ± 1.33, P = 0.0006; 2.62 ± 0.83 vs. 7.77 ± 1.32, P = 0.0026; 4.69 ± 1.13 vs.11.41 ± 1.92, P = 0.0054). Conclusion: HMGB1 blockade (anti-HMGB1 mAb) reduced leukocyte infiltration and suppressed inflammatory cytokine expression in this K14-VEGF transgenic mouse model, markedly reducing the severity of the psoriasis-like lesions. HMGB1 blockade might serve as a potential target for the treatment of psoriasis.


  • Open Access

    Níveis séricos aumentados de interferon lambda 1 / interleucina-29 em pacientes com psoríase vulgar

    by Li‐Xin Fu, Tao Chen, Zai‐Pei Guo, Na Cao, Li‐Wen Zhang, Pei‐Mei Zhou

  • Open Access

    Enhanced serum interferon-lambda 1/interleukin-29 levels in patients with psoriasis vulgaris

    by Li-Xin Fu, Tao Chen, Zai-Pei Guo, Na Cao, Li-Wen Zhang, Pei-Mei Zhou


  • Open Access

    Interleukin-35 inhibited the production of histamine and pro-inflammatory cytokines through suppression MAPKs pathway in HMC-1 cells

    by Li-Xin Fu, Tao Chen, Qiao-Mei Sun, Pei-Mei Zhou, Zai-Pei Guo

    Background: IL-35 is a newly anti-inflammatory cytokine that belongs to the IL-12 family. Mast cells, as one of the major effector cells in the immune response system, plays an important role in the pathogenesis of chronic spontaneous urticarial (CSU). Our study aims to explore the inhibited role of IL-35 in HMC-1.Methods: The effects of IL-35 on cell proliferation, cytokine expression, and histamine release in a human mast cell line (HMC­1) were investigated by CCK8, ELISA, or RT-PCR. The phosphorylation levels of ERK1/2, p38, and JNK1/2, in PMA plus A23187 induced HMC-1 cells was detected by Western Blot.Results: We found that IL-35 significantly inhibited the proliferation of HMC-1 cells stimulated by PMA and A23187. IL-35 also down-regulates the release of histamine and the mRNA expression of IL-6 and IL-17 in activated HMC-1. Furthermore, IL-35 markedly inhibited the phosphorylation levels of ERK1/2, p38, and JNK1/2, in PMA plus A23187 induced HMC-1 cells.Conclusions: This study provides the first observations on the inhibitory and anti-inflammatory effect of IL-35 in activated HMC-1 cells. We suggest that IL35 may play an inhibited role in the pathogenesis of CSU.


  • Open Access

    Interleukin-35 inhibited production of histamine and pro-inflammatory cytokines through suppression MAPKs pathway in HMC-1 cells

    by Lixin Fu, Tao Chen, Qiaomei Sun, Peimei Zhou, Zai-Pei Guo

    Background: IL-35 is a newly anti-inflammatory cytokine which belong to the IL-12 family. Mast cells, as one of the major effector cells in the immune response system, play important roles in the pathogenesis of chronic spontaneous urticarial (CSU). The aim of our study is to explore the inhibited role of IL-35 in HMC-1.Methods: The effects of IL-35 on cell proliferation, cytokine expression and histamine release in human mast cell line (HMC­1) were investigated by CCK8, ELISA or RT-PCR. The phosphorylation of ERK1/2, p38 and JNK1/2, in PMA and A23187 induced HMC-1 cells were detected by Western Blot.Results: We found that IL-35 significantly inhibited the proliferation of HMC-1 cells stimulated by PMA and A23187. IL-35 also down-regulates the released of histamine and the mRNA expression of IL-6 and IL-17 in activated HMC-1. Furthermore, IL-35 markedly inhibited the phosphorylation of ERK1/2, p38 and JNK1/2, in PMA and A23187 induced HMC-1 cells.Conclusions: This study provides first observations on the inhibitory and anti-inflammtory effect of IL-35 on activated HMC-1 cells. We suggest that IL35 may play an inhibited role in the pathogenesis of CSU.

  • Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial

    by Lun-Fei Liu, Ji-Su Chen, Jun Gu, Jin-Hua Xu, Hong-Zhong Jin, Xiao-Wen Pang, Gang Wang, Chen Yu, Zhi-Qiang Song, Zai-Pei Guo, et al.

    Etanercept biosimilar recombinant human tumour necrosis factor-α receptor II: IgG Fc fusion protein (rhTNFR-Fc, trade name Yisaipu) has shown good efficacy in the treatment of moderate-to-severe plaque psoriasis. To compare the efficacy and safety of rhTNFR-Fc plus methotrexate (MTX) and rhTNFR-Fc plus placebo in Chinese patients with moderate-to-severe plaque psoriasis. In this multicentre, randomized, placebo-controlled trial, patients with moderate-to-severe plaque psoriasis were enrolled and randomly assigned in a 1:1 ratio to receive rhTNFR-Fc plus MTX or rhTNFR-Fc plus placebo. The primary endpoint was the proportion of patients achieving Psoriasis Area and Severity Index improvement of at least 75% (PASI 75) from baseline at week 24. Adverse events (AEs) were recorded to evaluate safety. Efficacy analysis was performed using the intent-to-treat principle. A total of 466 patients were enrolled and randomly received rhTNFR-Fc plus MTX (combination group, n = 233) or rhTNFR-Fc plus placebo (monotherapy group, n = 233). PASI 75 at week 24 was significantly higher in the combination group than in the monotherapy group (81.86% vs. 65.50%, p < 0.001). Similar results were observed in other PASI improvement scores at week 12 [PASI 75, 62.39% vs. 44.54% (p < 0.001); PASI 50, 87.17% vs. 75.55% (p = 0.001); and PASI 90, 34.07% vs. 18.78% (p < 0.001)] and week 24 [PASI 50, 92.48% vs. 85.59% (p = 0.019); and PASI 90, 64.16% vs. 42.36% (p < 0.001)]. Significantly more patients had a static Physicians’ Global Assessment of clear or almost clear in the combination group than in the monotherapy group at week 12 (26.46% vs. 12.50%, p < 0.001) and week 24 (62.38% vs. 40.83%, p < 0.001). The most common AEs in the two groups were upper respiratory tract infection and abnormal liver function. The combination therapy of rhTNFR-Fc plus MTX was an effective therapy for moderate-to-severe plaque psoriasis with an acceptable safety and tolerability profile, indicating that it was feasible and well tolerated for patients.


  • Open Access

    Thrombin Induces Secretion of Multiple Cytokines and Expression of Protease-Activated Receptors in Mouse Mast Cell Line

    by Xiaobin Fang, Ren Liao, Yingyan Yu, Jingyi Li, Zaipei Guo, Tao Zhu

    Background. Thrombin could elicit degranulation of mast cells involved in numerous physiologic and pathologic processes; however, the detailed scrutiny of this procedure and further research of possible cell signaling pathways are lacking.Methods. P815 mouse mast cells were exposed to various concentrations of thrombin for 16 h. Expression of protease-activated receptor (PAR)1, PAR2, PAR3, and PAR4 mRNA in P815 was analyzed by quantitative real-time PCR (qRT-PCR) and the fittest concentration of thrombin was decided. Then, secretions of mediators from P815 stimulated by thrombin 0.2 U/ml were determined using enzyme-linked immunosorbent assay (ELISA) and Luminex liquichip; the possible cell signaling pathways were measured by immunoblotting. Furthermore, inhibition of thrombin inhibitor (hirudin), PAR1 inhibitor (SCH79797), and MAPK inhibitors (SB203580, PD98059, and SP600125) on the mediator section was evaluated by ELISA and Luminex liquichip.Results. Thrombin 0.2 U/ml induced the elevated expression of PAR1, PAR2, PAR3, and PAR4, as well as the increasing level of phospho-IκBα, phospho-SAPK/JNK MAPK, phospho-P38 MAPK (Thr180/Tyr182), and phospho-ERK1/2 MAPK (p44/42) in P815. Secretion of vascular endothelial growth factor (VEGF), tumor necrosis factor-α(TNF-α), interleukin- (IL-) 2, IL-6, chemokine ligand- (CCL-) 2, chemokine (C-X-C motif) ligand- (CXCL-) 1, and CXCL-5 from P815 increased apparently; this effect could be diminished by hirudin, whereas SCH79797 and MAPK inhibitors (SB203580, PD98059, and SP600125) diminish the secretions with weaker effect.Conclusion. We found the expression of PAR mRNA in P815, activation of signaling pathways of nuclear factor-kappaB (NF-κB), and mitogen-activated protein kinases (MAPKs) including C-Jun NH2-terminal kinase (JNK), P38, and extracellular signal-regulated kinase 1/2 (ERK1/2), and the release of multiple inflammatory mediators stimulated by thrombin, as well as the inhibition of the inflammatory releases by hirudin, SCH79797, and MAPK inhibitors including SB203580, PD98059, and SP600125.